New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD ...Middle East

STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the investigational subcutaneous formulation of LEQEMBI showing that it clears 14% more amyloid plaques as measured by PET compared to intravenous infusion...

Hence then, the article about new data from leqembi lecanemab irmb phase 3 clarity ad study and subcutaneous formulation presented at ctad was published today ( Thursday 26/10/2023 - 03:52 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD )

Also on site :

• Matt Damon’s Recent Rap Debut Was for Charity, Not a Career Pivot: ‘Kendrick Has Nothing to Worry About’
• Indie Studio A24 Defends Controversial Google AI Collab
• A Retiree's Practical Guide to Planning and Paying for That Once-in-a-Lifetime Vacation